Skip to main content
Erschienen in: World Journal of Urology 2/2020

27.04.2019 | Original Article

The prognostic impact of hexaminolevulinate-based bladder tumor resection in patients with primary non-muscle invasive bladder cancer treated with radical cystectomy

verfasst von: Markus Renninger, Omar Fahmy, Tina Schubert, Manuel Alexander Schmid, Fahmy Hassan, Arnulf Stenzl, Georgios Gakis

Erschienen in: World Journal of Urology | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To investigate whether hexaminolevulinate-based (HAL) bladder tumor resection (TURBT) impacts on outcomes of patients with primary non-muscle-invasive bladder cancer (NMIBC) who were eventually treated with radical cystectomy (RC).

Methods

A total of 131 consecutive patients exhibiting NMIBC at primary diagnosis were retrospectively investigated whether they had undergone any HAL-guided TURBT prior to RC. Uni- and multivariable analyses were used to evaluate the impact of HAL-TURBT on cancer-specific (CSS) and overall survival (OS). The median follow-up was 38 months (IQR 13–56).

Results

Of the 131 patients, 69 (52.7%) were managed with HAL- and 62 (47.3%) with white light (WL)-TURBT only prior to RC. HAL-TURBT was associated with a higher number of TURBTs prior to RC (p = 0.002) and administration of intravesical chemotherapy (p = 0.043). A trend towards a higher rate of tumor-associated immune cell infiltrates in RC specimens (p = 0.07) and a lower utilization rate of post-operative systemic chemotherapy (p = 0.10) was noted for patients who were treated with HAL-TURBT. The 5-year CSS/OS was 90.9%/74.5% for the HAL-group and 73.8%/55.8% for the WL-group (p = 0.042/0.038). In multivariable analysis, lymph node tumor involvement (p = 0.007), positive surgical margins (p = 0.001) and performance of WL-TURBT only (p = 0.040) were independent predictors for cancer-specific death.

Conclusions

The present data suggest that the resection of NMIBC under HAL exerts a beneficial impact on outcomes of patients who will need to undergo RC during their course of disease. This finding may be due to improved risk stratification as the resection under HAL may allow more patients to be treated timely and adequately.
Literatur
1.
Zurück zum Zitat Witjes JA, Comperat E, Cowan NC, De Santis M, Gakis G, Lebret T, Ribal MJ, Van der Heijden AG, Sherif A, European Association of U (2014) EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines. Eur Urol 65:778–792CrossRef Witjes JA, Comperat E, Cowan NC, De Santis M, Gakis G, Lebret T, Ribal MJ, Van der Heijden AG, Sherif A, European Association of U (2014) EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines. Eur Urol 65:778–792CrossRef
2.
Zurück zum Zitat Babjuk M, Bohle A, Burger M, Capoun O, Cohen D, Comperat EM, Hernandez V, Kaasinen E, Palou J, Roupret M, van Rhijn BW, Shariat SF, Soukup V, Sylvester RJ, Zigeuner R (2017) EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur Urol 71:447–461CrossRef Babjuk M, Bohle A, Burger M, Capoun O, Cohen D, Comperat EM, Hernandez V, Kaasinen E, Palou J, Roupret M, van Rhijn BW, Shariat SF, Soukup V, Sylvester RJ, Zigeuner R (2017) EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur Urol 71:447–461CrossRef
3.
Zurück zum Zitat Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, Newling DW, Kurth K (2006) Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49:465–466CrossRef Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, Newling DW, Kurth K (2006) Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49:465–466CrossRef
4.
Zurück zum Zitat Stenzl A, Eder I, Kostron H, Klocker H, Bartsch G (1996) Electromotive diffusion (EMD) and photodynamic therapy with delta-aminolaevulinic acid (delta-ALA) for superficial bladder cancer. J Photochem Photobiol 36:233–236CrossRef Stenzl A, Eder I, Kostron H, Klocker H, Bartsch G (1996) Electromotive diffusion (EMD) and photodynamic therapy with delta-aminolaevulinic acid (delta-ALA) for superficial bladder cancer. J Photochem Photobiol 36:233–236CrossRef
5.
Zurück zum Zitat Grossman HB, Stenzl A, Fradet Y, Mynderse LA, Kriegmair M, Witjes JA, Soloway MS, Karl A, Burger M (2012) Long-term decrease in bladder cancer recurrence with hexaminolevulinate enabled fluorescence cystoscopy. J Urol 188:58–62CrossRef Grossman HB, Stenzl A, Fradet Y, Mynderse LA, Kriegmair M, Witjes JA, Soloway MS, Karl A, Burger M (2012) Long-term decrease in bladder cancer recurrence with hexaminolevulinate enabled fluorescence cystoscopy. J Urol 188:58–62CrossRef
6.
Zurück zum Zitat Stenzl A, Burger M, Fradet Y, Mynderse LA, Soloway MS, Witjes JA, Kriegmair M, Karl A, Shen Y, Grossman HB (2010) Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer. J Urol 184:1907–1913CrossRef Stenzl A, Burger M, Fradet Y, Mynderse LA, Soloway MS, Witjes JA, Kriegmair M, Karl A, Shen Y, Grossman HB (2010) Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer. J Urol 184:1907–1913CrossRef
7.
Zurück zum Zitat Fotinos N, Campo MA, Popowycz F, Gurny R, Lange N (2006) 5-Aminolevulinic acid derivatives in photomedicine: characteristics, application and perspectives. Photochem Photobiol 82:994–1015CrossRef Fotinos N, Campo MA, Popowycz F, Gurny R, Lange N (2006) 5-Aminolevulinic acid derivatives in photomedicine: characteristics, application and perspectives. Photochem Photobiol 82:994–1015CrossRef
8.
Zurück zum Zitat Burger M, Grossman HB, Droller M, Schmidbauer J, Hermann G, Dragoescu O, Ray E, Fradet Y, Karl A, Burgues JP, Witjes JA, Stenzl A, Jichlinski P, Jocham D (2013) Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data. Eur Urol 64:846–854CrossRef Burger M, Grossman HB, Droller M, Schmidbauer J, Hermann G, Dragoescu O, Ray E, Fradet Y, Karl A, Burgues JP, Witjes JA, Stenzl A, Jichlinski P, Jocham D (2013) Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data. Eur Urol 64:846–854CrossRef
9.
Zurück zum Zitat Gakis G, Fahmy O (2016) Systematic review and meta-analysis on the impact of hexaminolevulinate- versus white-light guided transurethral bladder tumor resection on progression in non-muscle invasive bladder cancer. Bladder Cancer 2:293–300CrossRef Gakis G, Fahmy O (2016) Systematic review and meta-analysis on the impact of hexaminolevulinate- versus white-light guided transurethral bladder tumor resection on progression in non-muscle invasive bladder cancer. Bladder Cancer 2:293–300CrossRef
10.
Zurück zum Zitat Malmstrom PU, Hedelin H, Thomas YK, Thompson GJ, Durrant H, Furniss J (2009) Fluorescence-guided transurethral resection of bladder cancer using hexaminolevulinate: analysis of health economic impact in Sweden. Scand J Urol Nephrol 43:192–198CrossRef Malmstrom PU, Hedelin H, Thomas YK, Thompson GJ, Durrant H, Furniss J (2009) Fluorescence-guided transurethral resection of bladder cancer using hexaminolevulinate: analysis of health economic impact in Sweden. Scand J Urol Nephrol 43:192–198CrossRef
11.
Zurück zum Zitat Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, Boyd S, Skinner E, Bochner B, Thangathurai D, Mikhail M, Raghavan D, Skinner DG (2001) Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1054 patients. J Clin Oncol 19:666–675CrossRef Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, Boyd S, Skinner E, Bochner B, Thangathurai D, Mikhail M, Raghavan D, Skinner DG (2001) Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1054 patients. J Clin Oncol 19:666–675CrossRef
12.
Zurück zum Zitat Hautmann RE, de Petriconi RC, Pfeiffer C, Volkmer BG (2012) Radical cystectomy for urothelial carcinoma of the bladder without neoadjuvant or adjuvant therapy: long-term results in 1100 patients. Eur Urol 61:1039–1047CrossRef Hautmann RE, de Petriconi RC, Pfeiffer C, Volkmer BG (2012) Radical cystectomy for urothelial carcinoma of the bladder without neoadjuvant or adjuvant therapy: long-term results in 1100 patients. Eur Urol 61:1039–1047CrossRef
13.
Zurück zum Zitat van den Bosch S, Alfred Witjes J (2011) Long-term cancer-specific survival in patients with high-risk, non-muscle-invasive bladder cancer and tumour progression: a systematic review. Eur Urol 60:493–500CrossRef van den Bosch S, Alfred Witjes J (2011) Long-term cancer-specific survival in patients with high-risk, non-muscle-invasive bladder cancer and tumour progression: a systematic review. Eur Urol 60:493–500CrossRef
14.
Zurück zum Zitat Sobin LH, Wittekind C (2002) TNM classification of malignant tumors, 6th edn. Wiley, New York Sobin LH, Wittekind C (2002) TNM classification of malignant tumors, 6th edn. Wiley, New York
15.
Zurück zum Zitat Shim JW, Cho KS, Choi YD, Park YW, Lee DW, Han WS, Shim SI, Kim HJ, Cho NH (2008) Diagnostic algorithm for papillary urothelial tumors in the urinary bladder. Virchows Arch 452:353–362CrossRef Shim JW, Cho KS, Choi YD, Park YW, Lee DW, Han WS, Shim SI, Kim HJ, Cho NH (2008) Diagnostic algorithm for papillary urothelial tumors in the urinary bladder. Virchows Arch 452:353–362CrossRef
16.
Zurück zum Zitat Gakis G, Black PC, Bochner BH, Boorjian SA, Stenzl A, Thalmann GN, Kassouf W (2017) Systematic review on the fate of the remnant urothelium after radical cystectomy. Eur Urol 71:545–557CrossRef Gakis G, Black PC, Bochner BH, Boorjian SA, Stenzl A, Thalmann GN, Kassouf W (2017) Systematic review on the fate of the remnant urothelium after radical cystectomy. Eur Urol 71:545–557CrossRef
17.
Zurück zum Zitat Gakis G, Ngamsri T, Rausch S, Mischinger J, Todenhofer T, Schwentner C, Schmid MA, Hassan FA, Renninger M, Stenzl A (2015) Fluorescence-guided bladder tumour resection: impact on survival after radical cystectomy. World J Urol 33:1429–1437CrossRef Gakis G, Ngamsri T, Rausch S, Mischinger J, Todenhofer T, Schwentner C, Schmid MA, Hassan FA, Renninger M, Stenzl A (2015) Fluorescence-guided bladder tumour resection: impact on survival after radical cystectomy. World J Urol 33:1429–1437CrossRef
18.
Zurück zum Zitat Karaolides T, Skolarikos A, Bourdoumis A, Konandreas A, Mygdalis V, Thanos A, Deliveliotis C (2012) Hexaminolevulinate-induced fluorescence versus white light during transurethral resection of noninvasive bladder tumor: does it reduce recurrences? Urology 80:354–359CrossRef Karaolides T, Skolarikos A, Bourdoumis A, Konandreas A, Mygdalis V, Thanos A, Deliveliotis C (2012) Hexaminolevulinate-induced fluorescence versus white light during transurethral resection of noninvasive bladder tumor: does it reduce recurrences? Urology 80:354–359CrossRef
19.
Zurück zum Zitat Gakis G, Efstathiou J, Lerner SP, Cookson MS, Keegan KA, Guru KA, Shipley WU, Heidenreich A, Schoenberg MP, Sagaloswky AI, Soloway MS, Stenzl A, International Consultation on Urologic Disease-European Association of Urology Consultation on Bladder C (2013) ICUD-EAU International Consultation on Bladder Cancer 2012: Radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder. Eur Urol 63:45–57CrossRef Gakis G, Efstathiou J, Lerner SP, Cookson MS, Keegan KA, Guru KA, Shipley WU, Heidenreich A, Schoenberg MP, Sagaloswky AI, Soloway MS, Stenzl A, International Consultation on Urologic Disease-European Association of Urology Consultation on Bladder C (2013) ICUD-EAU International Consultation on Bladder Cancer 2012: Radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder. Eur Urol 63:45–57CrossRef
21.
Zurück zum Zitat Sternberg CN, Skoneczna I, Kerst JM et al (2015) Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N + M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial. Lancet Oncol 16:76–86CrossRef Sternberg CN, Skoneczna I, Kerst JM et al (2015) Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N + M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial. Lancet Oncol 16:76–86CrossRef
22.
Zurück zum Zitat Gschwend JE, Heck MM, Lehmann J, Rubben H, Albers P, Wolff JM, Frohneberg D, de Geeter P, Heidenreich A, Kalble T, Stockle M, Schnoller T, Stenzl A, Muller M, Truss M, Roth S, Liehr UB, Leissner J, Bregenzer T, Retz M (2019) Extended versus limited lymph node dissection in bladder cancer patients undergoing radical cystectomy: survival results from a prospective, randomized trial. Eur Urol 75:604–611CrossRef Gschwend JE, Heck MM, Lehmann J, Rubben H, Albers P, Wolff JM, Frohneberg D, de Geeter P, Heidenreich A, Kalble T, Stockle M, Schnoller T, Stenzl A, Muller M, Truss M, Roth S, Liehr UB, Leissner J, Bregenzer T, Retz M (2019) Extended versus limited lymph node dissection in bladder cancer patients undergoing radical cystectomy: survival results from a prospective, randomized trial. Eur Urol 75:604–611CrossRef
23.
Zurück zum Zitat Sylvester RJ, Brausi MA, Kirkels WJ, Hoeltl W, Calais Da Silva F, Powell PH, Prescott S, Kirkali Z, van de Beek C, Gorlia T, de Reijke TM, Group EG-UTC (2010) Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guerin, and bacillus Calmette-Guerin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. Eur Urol 57:766–773CrossRef Sylvester RJ, Brausi MA, Kirkels WJ, Hoeltl W, Calais Da Silva F, Powell PH, Prescott S, Kirkali Z, van de Beek C, Gorlia T, de Reijke TM, Group EG-UTC (2010) Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guerin, and bacillus Calmette-Guerin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. Eur Urol 57:766–773CrossRef
24.
Zurück zum Zitat Yu A, Mansure JJ, Solanki S, Siemens DR, Koti M, Dias ABT, Burnier MM, Brimo F, Kassouf W (2018) Presence of lymphocytic infiltrate cytotoxic T lymphocyte CD3+ , CD8+ , and immunoscore as prognostic marker in patients after radical cystectomy. PLoS One 13:e0205746CrossRef Yu A, Mansure JJ, Solanki S, Siemens DR, Koti M, Dias ABT, Burnier MM, Brimo F, Kassouf W (2018) Presence of lymphocytic infiltrate cytotoxic T lymphocyte CD3+ , CD8+ , and immunoscore as prognostic marker in patients after radical cystectomy. PLoS One 13:e0205746CrossRef
25.
Zurück zum Zitat Pichler R, Gruenbacher G, Culig Z, Brunner A, Fuchs D, Fritz J, Gander H, Rahm A, Thurnher M (2017) Intratumoral Th2 predisposition combines with an increased Th1 functional phenotype in clinical response to intravesical BCG in bladder cancer. Cancer Immunol Immunother 66:427–440CrossRef Pichler R, Gruenbacher G, Culig Z, Brunner A, Fuchs D, Fritz J, Gander H, Rahm A, Thurnher M (2017) Intratumoral Th2 predisposition combines with an increased Th1 functional phenotype in clinical response to intravesical BCG in bladder cancer. Cancer Immunol Immunother 66:427–440CrossRef
26.
Zurück zum Zitat Jarosch A, Sommer U, Bogner A, Reissfelder C, Weitz J, Krause M, Folprecht G, Baretton GB, Aust DE (2018) Neoadjuvant radiochemotherapy decreases the total amount of tumor infiltrating lymphocytes, but increases the number of CD8+/Granzyme B+ (GrzB) cytotoxic T-cells in rectal cancer. Oncoimmunology 7:e1393133CrossRef Jarosch A, Sommer U, Bogner A, Reissfelder C, Weitz J, Krause M, Folprecht G, Baretton GB, Aust DE (2018) Neoadjuvant radiochemotherapy decreases the total amount of tumor infiltrating lymphocytes, but increases the number of CD8+/Granzyme B+ (GrzB) cytotoxic T-cells in rectal cancer. Oncoimmunology 7:e1393133CrossRef
27.
Zurück zum Zitat Blando J, Sharma A, Higa MG, Zhao H, Vence L, Yadav SS, Kim J, Sepulveda AM, Sharp M, Maitra A, Wargo J, Tetzlaff M, Broaddus R, Katz MHG, Varadhachary GR, Overman M, Wang H, Yee C, Bernatchez C, Iacobuzio-Donahue C, Basu S, Allison JP, Sharma P (2019) Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer. Proc Nati Acad Sci USA 25:25. https://doi.org/10.1073/pnas.1811067116 CrossRef Blando J, Sharma A, Higa MG, Zhao H, Vence L, Yadav SS, Kim J, Sepulveda AM, Sharp M, Maitra A, Wargo J, Tetzlaff M, Broaddus R, Katz MHG, Varadhachary GR, Overman M, Wang H, Yee C, Bernatchez C, Iacobuzio-Donahue C, Basu S, Allison JP, Sharma P (2019) Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer. Proc Nati Acad Sci USA 25:25. https://​doi.​org/​10.​1073/​pnas.​1811067116 CrossRef
28.
Zurück zum Zitat Halkiotis K, Yova D, Pantelias G (1999) In vitro evaluation of the genotoxic and clastogenic potential of photodynamic therapy. Mutagenesis 14:193–198CrossRef Halkiotis K, Yova D, Pantelias G (1999) In vitro evaluation of the genotoxic and clastogenic potential of photodynamic therapy. Mutagenesis 14:193–198CrossRef
29.
Zurück zum Zitat Zenzen V, Zankl H (2004) In vitro evaluation of the cytotoxic and mutagenic potential of the 5-aminolevulinic acid hexylester-mediated photodynamic therapy. Mutat Res 561:91–100CrossRef Zenzen V, Zankl H (2004) In vitro evaluation of the cytotoxic and mutagenic potential of the 5-aminolevulinic acid hexylester-mediated photodynamic therapy. Mutat Res 561:91–100CrossRef
30.
Zurück zum Zitat Ekroll IK, Gederaas OA, Helander L, Hjelde A, Melo TB, Johnsson A (2011) Photo induced hexylaminolevulinate destruction of rat bladder cells AY-27. Photochem Photobiol Sci 10:1072–1079CrossRef Ekroll IK, Gederaas OA, Helander L, Hjelde A, Melo TB, Johnsson A (2011) Photo induced hexylaminolevulinate destruction of rat bladder cells AY-27. Photochem Photobiol Sci 10:1072–1079CrossRef
Metadaten
Titel
The prognostic impact of hexaminolevulinate-based bladder tumor resection in patients with primary non-muscle invasive bladder cancer treated with radical cystectomy
verfasst von
Markus Renninger
Omar Fahmy
Tina Schubert
Manuel Alexander Schmid
Fahmy Hassan
Arnulf Stenzl
Georgios Gakis
Publikationsdatum
27.04.2019
Verlag
Springer Berlin Heidelberg
Erschienen in
World Journal of Urology / Ausgabe 2/2020
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI
https://doi.org/10.1007/s00345-019-02780-0

Weitere Artikel der Ausgabe 2/2020

World Journal of Urology 2/2020 Zur Ausgabe

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.